The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
The group will need longer-term data to justify its huge valuation.
Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
The practicalities of actually selling the controversial new Alzheimer’s drug are proving increasingly difficult for Biogen.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
And four other potential targets that could make sense for the beleaguered group.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.